Title:
【発明の名称】腫瘍壊死因子媒介疾患の治療方法
Document Type and Number:
Japanese Patent JP2864434
Kind Code:
B2
Abstract:
Methods for treating TNF mediated diseases are provided. The methods comprise administering to patients in need thereof of therapeutically effective amount of a TNF inhibitor. In a preferred embodiment, the TNF inhibitor is selected from the group consisting of 30kDa TNF inhibitor, C105-PEG 3400 db and 40kDa TNF inhibitor, and the 40kDa TNF inhibitor is selected from the group consisting of full-length 40kDa TNF inhibitor, 40kDa TNF inhibitor DELTA 51 and 40kDa TNF inhibitor DELTA 53. A preferred method for producing the TNF inhibitors is by recombinant DNA technology.
More Like This:
| WO/2010/002763 | SOLID DOSAGE FORMULATIONS OF TELCAGEPANT POTASSIUM |
| WO/2000/030625 | USE OF PHOSPHONOFORMIC ACID DERIVATIVES FOR TREATING INFECTIONS |
| WO/2009/140484 | PROCESSES FOR PREPARING AMORPHOUS DRUG SUBSTANCE |
Inventors:
KAAMAIKURU DEBITSUDO EFU
SUMISU KURISUTOFUAA JII
TONPUSON ROBAATO SHII
RATSUSERU DEBORA
KONO TADAHIKO
SUMISU KURISUTOFUAA JII
TONPUSON ROBAATO SHII
RATSUSERU DEBORA
KONO TADAHIKO
Application Number:
JP50459792A
Publication Date:
March 03, 1999
Filing Date:
January 17, 1992
Export Citation:
Assignee:
SAINAAGEN INC
International Classes:
A61K31/00; A61K38/02; A61K38/16; A61K38/00; A61K47/34; A61P1/00; A61P9/00; A61P11/00; A61P11/16; A61P19/00; A61P19/02; A61P29/00; A61P31/00; A61P31/04; A61P37/00; A61P43/00; C07K14/525; C07K14/715; C12P21/00; C12P21/02; (IPC1-7): A61K38/00; A61K38/00; C12P21/00
Domestic Patent References:
| JP2117700A | ||||
| JP2200A | ||||
| JP4505014A | ||||
| JP4507195A |
Other References:
【文献】欧州公開393438(EP,A1)
【文献】欧州公開422339(EP,A1)
【文献】欧州公開422339(EP,A1)
Attorney, Agent or Firm:
Akira Asamura (3 outside)